[시장보고서]헌터증후군 치료 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 투여 경로별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

헌터증후군 치료 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 투여 경로별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Hunter Syndrome Treatment Market Size, Share & Trends Analysis Report By Type (Enzyme Replacement Therapy, Hematopoietic Stem Cell Transplant), By Route Of Administration, By End Use, By Region, And Segment Forecasts, 2025 - 2030

상품코드 : 1587514

리서치사 : Grand View Research, Inc.

발행일 : 2024년 10월

페이지 정보 : 영문 100 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,302,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 9,698,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 12,488,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

헌터증후군 치료 시장 성장과 동향:

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 헌터증후군 치료 시장 규모는 2025년부터 2030년까지 연평균 5.3%로 확대되어 2030년에는 17억 8,000만 달러에 달할 것으로 예상됩니다.

높은 미충족 수요, 풍부한 파이프라인, 희귀질환에 대한 인식 개선, 새로운 치료법 개발을 위한 활발한 R&D 활동이 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다.

Mucopolysaccharidosis II형(MPS II)이라고도 불리는 헌터증후군은 이두론산-2-설파타제 효소의 결핍이나 기능 장애로 인해 발생하는 희귀한 유전 질환입니다. 미국 국립 신경장애 및 뇌졸중 연구소가 발표한 자료에 따르면, MPS II 증후군은 남성 출생아 10만-15만 명당 1명꼴로 발생한다고 합니다.

현재 헌터증후군의 치료제로 승인된 치료법은 없습니다. 효소대체요법(ERT), 조혈모세포이식(HSCT) 등 현재 사용 가능한 치료 옵션은 증상 완화 및 질병 진행에 따른 합병증 관리에 초점을 맞추고 있습니다. 샤이어의 엘라프라제(이둘루설파제)는 헌터증후군 치료로서 세계에서 유일하게 사용 가능한 주요 의약품이며, GC녹십자의 헌터제(이둘루설파제 베타)는 한국에서만 승인된 치료제입니다.

주요 기업들은 제품 개발 및 새로운 치료제로서의 승인을 받기 위해 광범위한 연구개발 활동에 집중하고 있습니다. 가까운 시일 내에 이러한 신규 치료제의 출시는 헌터증후군 치료 시장의 성장을 크게 촉진할 것으로 예상됩니다. 예를 들어, 2018년 5월, REGENXBIO Inc.는 이 질환을 치료하기 위한 신약 후보물질 RGX-121에 대해 미국 FDA의 패스트트랙 지정을 받았습니다.

헌터증후군 치료 시장 보고서 하이라이트

정맥 투여가 시장을 주도하고 2024년 72.3%의 최대 매출 점유율을 차지했습니다.
효소 대체 요법(ERT)은 효소 이두론산-2-설파타제 결핍에 대처할 수 있는 능력으로 2024년 57.3%의 가장 큰 매출 점유율을 차지하며 시장을 주도했습니다.
시장은 병원이 지배적인 위치를 차지하고 있으며, 종합적인 치료와 고급 의료 자원을 제공 할 수있는 능력으로 인해 2024년에 63.1%의 최대 수익 점유율을 차지했습니다.
북미 헌터증후군 치료 시장은 2024년 37.5%의 최대 매출 점유율을 차지하며 세계 시장을 장악했습니다.

지역별 시장 점유율 분석, 2024년 및 2030년
지역 시장 대시보드
시장 규모, 예측 동향 분석, 2018년에서 2030년 :
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 노르웨이
- 덴마크
- 스웨덴
아시아태평양
- 일본
- 중국
- 인도
- 한국
- 호주
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트

제8장 경쟁 상황

참여자 개요
기업의 시장 포지션 분석
기업 분류
전략 매핑
기업 개요/상장 기업
- Takeda Pharmaceutical Company Limited
- F. Hoffmann-La Roche Ltd.
- Abbott
- Denali Therapeutics
- Medtronic
- Johnson & Johnson Services, Inc.
- GSK Plc.
- Bayer AG
- Zimmer Biomet
- Stryker Corporation
- Homology Medicines, Inc.
- Novartis AG

ksm

영문 목차

영문목차

Hunter Syndrome Treatment Market Growth & Trends:

The global hunter syndrome treatment market size is expected to reach a value of USD 1.78 billion by 2030, expanding at a CAGR of 5.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. High unmet needs, robust pipeline, increasing awareness about this rare disease and growing R&D activities for the development of novel therapies are expected to drive market growth over the forecast period.

Hunter syndrome, also referred as mucopolysaccharidosis type II (MPS II), is a rare genetic disorder caused by the missing or malfunctioning iduronate-2-sulfatase enzyme. According to the data published by the National Institute of Neurological Disorders and Stroke, MPS II syndrome occurs in around 1 in every 100,000 to 150,000 male births.

Presently, there are no approved curative therapies for the treatment of Hunter syndrome. The available treatment options such as enzyme replacement therapy (ERT) and hematopoietic stem cell transplant (HSCT) are focused on providing symptomatic relief and management of complications associated with disease progression. Shire plc's Elaprase (idursulfase) is the only key drug available for the treatment of Hunter syndrome worldwide, with GC Pharma's Hunterase (idursulfase beta) being approved only in South Korea.

Key players are focused on extensive R&D activities for product development and gaining approval as novel therapies. Launch of such novel therapies in the near future is expected to significantly fuel the Hunter syndrome treatment market growth. For instance, in May 2018, REGENXBIO Inc. received the U.S. FDA's Fast Track designation for its novel drug candidate RGX-121, indicated for the disease treatment.

Hunter Syndrome Treatment Market Report Highlights:

The intravenous segment led the market and accounted for the largest revenue share of 72.3% in 2024 attributed to its established effectiveness in delivering enzyme replacement therapies (ERT).
Enzyme replacement therapy (ERT) led the market and accounted for the largest revenue share of 57.3% in 2024 driven by its ability to address the deficiency of the enzyme iduronate-2-sulfatase.
Hospitals held the dominant position in the market, accounting for the largest revenue share of 63.1% in 2024 attributed to their capacity to provide comprehensive care and advanced medical resources.
North America hunter syndrome treatment market dominated the global market and accounted for the largest revenue share of 37.5% in 2024 attributed to a combination of advanced healthcare infrastructure and increasing awareness of rare diseases.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Type
- 1.2.2. Technology
- 1.2.3. Test
- 1.2.4. Type
- 1.2.5. End Use
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
1.6. Information Analysis
- 1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
- 1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Hunter Syndrome Treatment Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
  - 3.3.1.1. Supplier power
  - 3.3.1.2. Buyer power
  - 3.3.1.3. Substitution threat
  - 3.3.1.4. Threat of new entrant
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTLE Analysis

Chapter 4. Hunter Syndrome Treatment Market: Type Business Analysis

4.1. Type Market Share, 2024 & 2030
4.2. Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
4.4. Enzyme Replacement Therapy (ERT)
- 4.4.1. Enzyme Replacement Therapy (ERT) Market, 2018 - 2030 (USD Million)
4.5. Hematopoietic Stem Cell Transplant (HSCT)
- 4.5.1. Hematopoietic Stem Cell Transplant (HSCT) Market, 2018 - 2030 (USD Million)
4.6. Others
- 4.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Hunter Syndrome Treatment Market: Route of Administration Business Analysis

5.1. Route of Administration Market Share, 2024 & 2030
5.2. Route of Administration Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
5.4. Intravenous
- 5.4.1. Intravenous Market, 2018 - 2030 (USD Million)
5.5. Intracerebroventricular (ICV)/ Intrathecal
- 5.5.1. Intracerebroventricular (ICV)/Intrathecal Market, 2018 - 2030 (USD Million)

Chapter 6. Hunter Syndrome Treatment Market: End Use Business Analysis

6.1. End Use Market Share, 2024 & 2030
6.2. End Use Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
6.4. Hospitals
- 6.4.1. Hospitals Market, 2018 - 2030 (USD Million)
6.5. Specialty Clinics
- 6.5.1. Specialty Clinics Market, 2018 - 2030 (USD Million)
6.6. Others
- 6.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Hunter Syndrome Treatment Market: Regional Estimates & Trend Analysis

7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
- 7.4.1. North America Hunter Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. U.S.
  - 7.4.2.1. Key country dynamics
  - 7.4.2.2. Regulatory framework
  - 7.4.2.3. Competitive insights
  - 7.4.2.4. U.S. hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Canada
  - 7.4.3.1. Key country dynamics
  - 7.4.3.2. Regulatory framework
  - 7.4.3.3. Competitive insights
  - 7.4.3.4. Canada hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.4.4. Mexico
  - 7.4.4.1. Key country dynamics
  - 7.4.4.2. Regulatory framework
  - 7.4.4.3. Competitive insights
  - 7.4.4.4. Mexico hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.5. Europe
- 7.5.1. Europe Hunter Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. UK
  - 7.5.2.1. Key country dynamics
  - 7.5.2.2. Regulatory framework
  - 7.5.2.3. Competitive insights
  - 7.5.2.4. UK hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Germany
  - 7.5.3.1. Key country dynamics
  - 7.5.3.2. Regulatory framework
  - 7.5.3.3. Competitive insights
  - 7.5.3.4. Germany hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.4. France
  - 7.5.4.1. Key country dynamics
  - 7.5.4.2. Regulatory framework
  - 7.5.4.3. Competitive insights
  - 7.5.4.4. France hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.5. Italy
  - 7.5.5.1. Key country dynamics
  - 7.5.5.2. Regulatory framework
  - 7.5.5.3. Competitive insights
  - 7.5.5.4. Italy hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.6. Spain
  - 7.5.6.1. Key country dynamics
  - 7.5.6.2. Regulatory framework
  - 7.5.6.3. Competitive insights
  - 7.5.6.4. Spain hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.7. Norway
  - 7.5.7.1. Key country dynamics
  - 7.5.7.2. Regulatory framework
  - 7.5.7.3. Competitive insights
  - 7.5.7.4. Norway hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.8. Denmark
  - 7.5.8.1. Key country dynamics
  - 7.5.8.2. Regulatory framework
  - 7.5.8.3. Competitive insights
  - 7.5.8.4. Denmark hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.9. Sweden
  - 7.5.9.1. Key country dynamics
  - 7.5.9.2. Regulatory framework
  - 7.5.9.3. Competitive insights
  - 7.5.9.4. Sweden hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.6. Asia Pacific
- 7.6.1. Asia Pacific Hunter Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. Japan
  - 7.6.2.1. Key country dynamics
  - 7.6.2.2. Regulatory framework
  - 7.6.2.3. Competitive insights
  - 7.6.2.4. Japan hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.6.3. China
  - 7.6.3.1. Key country dynamics
  - 7.6.3.2. Regulatory framework
  - 7.6.3.3. Competitive insights
  - 7.6.3.4. China hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.6.4. India
  - 7.6.4.1. Key country dynamics
  - 7.6.4.2. Regulatory framework
  - 7.6.4.3. Competitive insights
  - 7.6.4.4. India hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.6.5. South Korea
  - 7.6.5.1. Key country dynamics
  - 7.6.5.2. Regulatory framework
  - 7.6.5.3. Competitive insights
  - 7.6.5.4. South Korea hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.6.6. Australia
  - 7.6.6.1. Key country dynamics
  - 7.6.6.2. Regulatory framework
  - 7.6.6.3. Competitive insights
  - 7.6.6.4. Australia hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.6.7. Thailand
  - 7.6.7.1. Key country dynamics
  - 7.6.7.2. Regulatory framework
  - 7.6.7.3. Competitive insights
  - 7.6.7.4. Thailand hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.7. Latin America
- 7.7.1. Latin America Hunter Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.2. Brazil
  - 7.7.2.1. Key country dynamics
  - 7.7.2.2. Regulatory framework
  - 7.7.2.3. Competitive insights
  - 7.7.2.4. Brazil hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.7.3. Argentina
  - 7.7.3.1. Key country dynamics
  - 7.7.3.2. Regulatory framework
  - 7.7.3.3. Competitive insights
  - 7.7.3.4. Argentina hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
7.8. MEA
- 7.8.1. MEA Hunter Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.2. South Africa
  - 7.8.2.1. Key country dynamics
  - 7.8.2.2. Regulatory framework
  - 7.8.2.3. Competitive insights
  - 7.8.2.4. South Africa hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.8.3. Saudi Arabia
  - 7.8.3.1. Key country dynamics
  - 7.8.3.2. Regulatory framework
  - 7.8.3.3. Competitive insights
  - 7.8.3.4. Saudi Arabia hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.8.4. UAE
  - 7.8.4.1. Key country dynamics
  - 7.8.4.2. Regulatory framework
  - 7.8.4.3. Competitive insights
  - 7.8.4.4. UAE hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.8.5. Kuwait
  - 7.8.5.1. Key country dynamics
  - 7.8.5.2. Regulatory framework
  - 7.8.5.3. Competitive insights
  - 7.8.5.4. Kuwait hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
- 8.5.1. Takeda Pharmaceutical Company Limited
  - 8.5.1.1. Overview
  - 8.5.1.2. Financial performance
  - 8.5.1.3. Type benchmarking
  - 8.5.1.4. Strategic initiatives
- 8.5.2. F. Hoffmann-La Roche Ltd.
  - 8.5.2.1. Overview
  - 8.5.2.2. Financial performance
  - 8.5.2.3. Type benchmarking
  - 8.5.2.4. Strategic initiatives
- 8.5.3. Abbott
  - 8.5.3.1. Overview
  - 8.5.3.2. Financial performance
  - 8.5.3.3. Type benchmarking
  - 8.5.3.4. Strategic initiatives
- 8.5.4. Denali Therapeutics
  - 8.5.4.1. Overview
  - 8.5.4.2. Financial performance
  - 8.5.4.3. Type benchmarking
  - 8.5.4.4. Strategic initiatives
- 8.5.5. Medtronic
  - 8.5.5.1. Overview
  - 8.5.5.2. Financial performance
  - 8.5.5.3. Type benchmarking
  - 8.5.5.4. Strategic initiatives
- 8.5.6. Johnson & Johnson Services, Inc.
  - 8.5.6.1. Overview
  - 8.5.6.2. Financial performance
  - 8.5.6.3. Type benchmarking
  - 8.5.6.4. Strategic initiatives
- 8.5.7. GSK Plc.
  - 8.5.7.1. Overview
  - 8.5.7.2. Financial performance
  - 8.5.7.3. Type benchmarking
  - 8.5.7.4. Strategic initiatives
- 8.5.8. Bayer AG
  - 8.5.8.1. Overview
  - 8.5.8.2. Financial performance
  - 8.5.8.3. Type benchmarking
  - 8.5.8.4. Strategic initiatives
- 8.5.9. Zimmer Biomet
  - 8.5.9.1. Overview
  - 8.5.9.2. Financial performance
  - 8.5.9.3. Type benchmarking
  - 8.5.9.4. Strategic initiatives
- 8.5.10. Stryker Corporation
  - 8.5.10.1. Overview
  - 8.5.10.2. Financial performance
  - 8.5.10.3. Type benchmarking
  - 8.5.10.4. Strategic initiatives
- 8.5.11. Homology Medicines, Inc.
  - 8.5.11.1. Overview
  - 8.5.11.2. Financial performance
  - 8.5.11.3. Type benchmarking
  - 8.5.11.4. Strategic initiatives
- 8.5.12. Novartis AG
  - 8.5.12.1. Overview
  - 8.5.12.2. Financial performance
  - 8.5.12.3. Type benchmarking
  - 8.5.12.4. Strategic initiatives

한글목차

헌터증후군 치료 시장 성장과 동향:

헌터증후군 치료 시장 보고서 하이라이트

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 헌터증후군 치료 시장 변수, 동향, 범위

제4장 헌터증후군 치료 시장 : 유형별 비즈니스 분석

제5장 헌터증후군 치료 시장 : 투여 경로별 비즈니스 분석

제6장 헌터증후군 치료 시장 : 최종 용도별 비즈니스 분석

제7장 헌터증후군 치료 시장 : 지역별 추정·동향 분석